Orbifloxacin: A Review of Properties, Its Antibacterial Activities, Pharmacokinetic/Pharmacodynamic Characteristics, Therapeutic Use, and Analytical Methods

Critical Reviews in Analytical Chemistry

Volumn 43, Issue 2, 2013, Pages 79-99

  Cazedey, Edith Cristina Laignier ^a   Salgado, Hérida Regina Nunes ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

analytical methods; fluoroquinolones; Orbifloxacin; pharmacodynamics; pharmacokinetics; resistance; review; veterinary drug

Indexed keywords

ANALYTICAL METHOD; ANTI-BACTERIAL ACTIVITY; BACTERIAL INFECTIONS; CLINICAL EFFECTS; CLINICAL EFFICACY; ENTEROBACTERIACEAE; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIUM; IN-VITRO; MINIMUM INHIBITORY CONCENTRATION; NATURALLY OCCURRING; ORBIFLOXACIN; PHARMACOKINETIC PARAMETERS; SCIENTIFIC LITERATURE; SOFT TISSUE; SOFT TISSUE INFECTIONS; THERAPEUTIC USE; THIRD GENERATION; URINARY TRACT INFECTIONS; VETERINARY DRUGS;

AGRICULTURE; ANIMALS; ELECTRIC RESISTANCE; PHARMACODYNAMICS; RESPIRATORY SYSTEM; REVIEWS; TISSUE;

PHARMACOKINETICS;

ANTIMICROBIAL ACTIVITY; DOSE-RESPONSE RELATIONSHIP; DRUG; EFFICIENCY MEASUREMENT; INHIBITION; REACTION KINETICS;

ANIMALIA; BACTERIA (MICROORGANISMS); BOS; CAMELIDAE; CANIS FAMILIARIS; CAPRA HIRCUS; CORYNEBACTERINEAE; ENTEROBACTERIACEAE; EQUIDAE; NEGIBACTERIA; ORYCTOLAGUS CUNICULUS; OVIS ARIES; POSIBACTERIA; SUIDAE;

EID: 84874490796     PISSN: 10408347     EISSN: 15476510     Source Type: Journal    
DOI: 10.1080/10408347.2012.746855     Document Type: Article

References (92)

1. Abd El-Aty, A. M., Choi, J.-H., Ko, M.-W., Khay, S., Goudah, A., Shin, H.-C., Kim, J.-S., Chang, B.-J., Lee, C.-H. and Shim, J.-H. 2009. Approaches for Application of Sub and Supercritical Fluid Extraction for Quantification of Orbifloxacin from Plasma and Milk: Application to Disposition Kinetics. Anal. Chim. Acta, 631: 108-115.
2. Abo-El-Sooud, K. and Goudah, A. 2009. nfluence of Pasteurella multocida Infection on the Pharmacokinetic Behavior of Marbofloxacin after Intravenous and Intramuscular Administrations in Rabbits. J. Vet. Pharmacol. Ther, 33: 63-68.
3. Albarellos, G. A. and Landoni, M. F. 2009. Current Concepts on the Use of Antimicrobials in Cats. Vet. J., 180: 304-316.
4. Amidon, G. L., Lennernas, H., Shah, V. P. and Crison, J. R. A. 1995. Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of an In Vitro Drug Product Dissolution and In Vivo Bioavailability. Pharm. Res, 12: 413-420.
5. Authier, S., Paquette, D., Labrecque, O. and Messier, S. 2006. Comparison of Susceptibility to Antimicrobials of Bacterial Isolates from Companion Animals in a Veterinary Diagnostic Laboratory in Canada between 2 Time Points 10 Years Apart. Can. Vet. J, 47: 774-778.
6. Ball, P. 2000. Quinolone Generations: Natural History or Natural Selection. J. Antimicrob. Chemother., 46: 17-24.
7. Boothe, D. M., Boeckh, A., Simpson, R. B. and Dubose, K. 2006. Comparison of Pharmacodynamic and Pharmacokinetic Indices of Efficacy for 5 Fluoroquinolones toward Pathogens of Dogs and Cats. J. Vet. Intern. Med., 20: 1297-1306.
8. 2011. British Pharmacopoeia, Vol. 1, 88-90. London: Her Majesty's Stationery Office.
9. Cazedey, E. C. L. and Salgado, H. R. N. 2011. Development and Validation of a Microbiological Agar Assay for Determination of Orbifloxacin in Pharmaceutical Preparations. Pharmaceutics, 3: 572-581.
10. Cazedey, E. C. L., Othman, A., Garg, S. and Salgado, H. R. N. 2011. A Validated Stability-Indicating LC Method for Orbifloxacin in the Presence of Degradation Products. Curr. Pharm. Anal, 7(3): 176-181.
11. Cho, S., Fossler, C. P., Diez-Gonzalez, F., Wells, S. J., Hedberg, C. W., Kaneene, J. B., Ruegg, P. L., Warnick, L. D. and Bender, J. B. 2007. Antimicrobial Susceptibility of Shiga Toxin-Producing Escherichia coli Isolated from Organic Dairy Farms, Conventional Dairy Farms, and County Fairs in Minnesota. Foodborne Pathog. Dis., 4(2): 178-186.
12. Cho, H. J., Yi, H., Cho, S. M., Lee, D. G., Cho, K., Abd-El-Aty, A. M., Shim, J. H., Lee, S. H., Jeong, J. Y. and Shin, H. C. 2010. Single-Step Extraction Followed by LC for Determination of (Fluoro)Quinolone Drug Residues in Muscle, Eggs, and Milk. J. Sep. Sci., 33(8): 1034-1043.
13. Chonan, T., Fujimoto, T., Inoue, M., Tazawa, T. and Ogawa, H. 2008. Multiresidue Determination of Quinolones in Animal and Fishery Products by HPLC [in Japanese]. Shokuhin Eiseiqaku Zasshi, 49(3): 244-248.
14. Clinical and Laboratory Standards Institute (CLSI). 2002. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard, 2nd ed., Wayne, Penn: Clinical and Laboratory Standards Institute. CLSI document M31-A2
15. Clinical and Laboratory Standards Institute (CLSI). 2004. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard-Information Supplement, Wayne, Penn: Clinical and Laboratory Standards Institute. CLSI document M31-S1
16. Clinical and Laboratory Standards Institute (CLSI). 2008. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard, 3rd ed., Wayne, Penn: Clinical and Laboratory Standards Institute. CLSI document M31-A3
17. Clinical and Laboratory Standards Institute (CLSI). 2009. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, 8th ed., Wayne, Penn: Clinical and Laboratory Standards Institute. CLSI document M07-A8
18. Coelho-Baptista, B., Costa, M., Duarte Correia, J. and Pomba, C. 2003. In vitro Activity of Enrofloxacin, Marbofloxacin, Orbifloxacin and Ciprofloxacin against Clinical Strains of Staphylococcus intermedius Isolated from Dogs in Portugal. J. Vet. Pharmacol. Ther, 26(Suppl. 1): 155-156.
19. Cox, S. K. 2007. Allometric Scaling of Marbofloxacin, Moxifloxacin, Danofloxacin and Difloxacin Pharmacokinetics: A Retrospective Analysis. J. Vet. Pharmacol. Ther., 30: 381-386.
20. Davis, J. L., Papich, M. G. and Weingarten, A. 2006. The Pharmacokinetics of Orbifloxacin in the Horse Following Oral and Intravenous Administration. J. Vet. Pharmacol. Ther., 29: 191-197.
21. Duan, J. and Yuan, Z. 2001. Development of an Indirect Competitive ELISA for Ciprofloxacin Residues in Food Animal Edible Tissues. J. Agric. Food Chem., 49: 1087-1089.
22. Elias, G., Lee, J.-S., Hwang, M.-H., Park, Y.-S., Cho, K.-H., Kim, Y.-H. and Park, S.-C. 2009. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Integration of Orbifloxacin in Korean Hanwoo Cattle. J. Vet. Pharmacol. Ther., 32: 219-228.
23. Engberg, J., Aarestrup, F. M., Taylor, D. E., Gerner-Smidt, P. and Nachamkin, I. 2001. Quinolone and Macrolide Resistance in Campylobacter jejuni and C. coli: Resistance Mechanisms and Trends in Human Isolates. Emerg. Infect. Dis, 7: 24-34.
24. Esaki, H., Asai, T., Kojima, A., Ishihara, K., Morioka, A., Tamura, Y. and Takahashi, T. 2005. Antimicrobial Susceptibility of Mannheimia haemolytica Isolates from Cattle on Japan from 2001 to 2002. J. Vet. Med. Sci, 67(1): 75-77.
25. Fujii, T., Takatsu, S., Stegemann, M., Ogata, M. and Kamata, S. 2007. Clinical Efficacy and Safety of an Injectable Formulation of Cefovecin in the Treatment of Bacterial Skin Infections of Dogs. Jpn. J. Vet. Dermatol, 13(2): 81-88.
26. Fujita, M., Tamura, W., Tozawa, T. and Kometani, T. 2008. Application of Simultaneous Determination Method of Residual Veterinary Drugs to Processed Foods [in Japanese]. Shokuhin Eiseiqaku Zasshi, 49(6): 416-421.
27. Ganière, J. P., Médaille, C. and Etoré, F. 2004. In Vitro Antimicrobial Activity of Orbifloxacin against Staphylococcus intermedius Isolates from Canine Skin and Ear Infections. Res. Vet. Sci, 77: 67-71.
28. García, M. A., Solans, C., Aramayona, J. J., Rueda, S. and Bregante, M. A. 1999. Determination of Orbifloxacin in Rabbit Plasma by High-Performance Liquid Chromatography with Fluorescence Detection. J. Chromatogr. Sci., 37(6): 199-202.
29. Gebru, E., Lee, J.-S., Chang, Z.-Q., Hwang, M.-H., Cheng, H. and Park, S.-C. 2009. Integration of Pharmacokinetic and Pharmacodynamic Indices of Orbifloxacin in Beagle Dogs after a Single Intravenous and Intramuscular Administration. Antimicrob. Agents Chemother., 53(7): 3024-3029.
30. Gottlieb, S., Wigney, D. I., Martin, P. A., Norris, J. M., Malik, R. and Govendir, M. 2008. Susceptibility of Canine and Feline Escherichia coli and Canine Staphylococcus intermedius Isolates to Fluoroquinolones. Aust. Vet. J, 86(4): 147-152.
31. Goudah, A. and Abo-El-Sooud, K. 2008. Pharmacokinetics and Milk Penetration of Orbifloxacin after Intravenous and Intramuscular Injections to Dromedary Lactating Camels (Camelus Dromedaries). J. Vet. Pharmacol. Ther., 31: 276-280.
32. Goudah, A., Cho, H. J., Shin, H. C., Shim, J. H., Regmi, N. L., Shimoda, M. and Abd-El-Aty, A. M. 2009. Pharmacokinetics and Milk Distribution Characteristics of Orbifloxacin Following Intravenous and Intramuscular Injection in Lactating Ewes. J. Vet. Pharmacol. Ther., 32(4): 338-344.
33. Haines, G. R., Brown, M. P., Gronwall, R. R., Merritt, K. A. and Baltzley, L. K. 2001. Pharmacokinetics of Orbifloxacin and Its Concentration in Body Fluids and in Endometrial Tissues of Mares. Can. J. Vet. Res., 65: 181-187.
34. Hariharan, H., Coles, M., Poole, D., Lund, L. and Page, R. 2006. Update on Antimicrobial Susceptibilities of Bacterial Isolates from Canine and Feline Otitis Externa. Can. Vet. J, 47(3): 253-255.
35. Heinen, E. Comparative Pharmacokinetics of Enrofloxacin, Marbofloxacin, and Orbifloxacin in Cats after Single Oral Administration [Abstract L11]. Proceedings of the Eighth International Congress of the European Association for Veterinary Pharmacology and Toxicology, Israel, Oxford UK: Blackwell Science, Ltd.
36. Heinen, E. 2002. Comparative Serum Pharmacokinetics of the Fluoroquinolones Enrofloxacin, Difloxacin, Marbofloxacin, and Orbifloxacin in Dogs after Single Oral Administration. J. Vet. Pharmacol. Ther., 25: 1-5.
37. Hung, S.-W., Shih, C.-W., Chen, B.-R., Tu, C.-Y., Ling, Y.-F., Tsou, L. T., Ho, S. P. and Wang, W. S. A. 2007. New Detection Technique for Fluoroquinolone-Conjugated Proteins by High Performance Liquid Chromatography with UV/Fluorescence Detectors. J. Food Drug Anal., 15(1): 71-74.
38. Ibrahem, M. D., Atta, A. H. and Shalaby, M. A. 2010. Bioavailability of Orbifloxacin in African Sharptooth Catfish, Clarias gariepinus, and Its Efficacy in Control of Induced Edwardsiellosis. J. Am. Sci., 6(6): 236-244.
39. Ihrke, P. J. 1984. Therapeutic Strategies Involving Antimicrobial Treatment of the Skin in Small Animals. J. Am. Vet. Med. Assoc, 185: 1165-1168.
40. Ihrke, P. J., Papich, M. G. and Demanuelle, T. C. 1999. The Use of Fluoroquinolones in Veterinary Dermatology. Vet. Dermatol., 10: 193-204.
41. Johnston, L., Mackay, L. and Croft, M. 2002. Determination of Quinolones and Fluoroquinolones in Fish Tissue and Seafood by High-Performance Liquid Chromatography with Electrospray Ionisation Tandem Mass Spectrometric Detection. J. Chromatogr. A, 982: 97-109.
42. Kajita, H. and Hatakeyama, E. 2008. Simultaneous Determination of Residual Veterinary Drugs in Livestock Products and Fish by Liquid Chromatography with Tandem Mass Spectrometry [in Japanese]. Shokuhin Eiseiqaku Zasshi, 49(6): 381-389.
43. Kay-Mugford, P. A., Weingarten, A. J., Ngoh, M., Zolynas, R., White, A., Katz, T., Simmons, R. and Varma, K. J. 2002. Determination of Plasma and Skin Concentrations of Orbifloxacin in Dogs with Clinically Normal Skin and Dogs with Pyoderma. Vet. Ther., 3(4): 402-408.
44. Kumazawa, J. and Yagisawa, M. 2002. The History of Antibiotics: The Japanese Story. J. Infect. Chemother., 8: 125-133.
45. Li, Y. L., Hao, X. L., Ji, B. Q., Xu, C. L., Chen, W., Shen, C. Y. and Ding, T. 2009. Rapid Determination of 19 Quinolone Residues in Spiked Fish and Pig Muscle by High-Performance Liquid Chromatography (HPLC) Tandem Mass Spectrometry. Food Addit. Contam., 26(3): 306-313.
46. Linder, J. S., Huang, E. S., Steinman, M. A., Gonzales, R. and Stafford, R. S. 2005. Fluoroquinolone Prescribing in the United States: 1995 to 2002. Am. J. Med., 118(3): 259-268.
47. Llinàs, A., Glen, R. C. and Goodman, J. M. 2008. Solubility Challenge: Can You Predict Solubilities of 32 Molecules Using a Database of 100 Reliable Measurements?. J. Chem. Inf. Model, 48: 1289-1303.
48. Llorent-Martínez, E. J., Ortega-Barrales, P., Molina-Díaz, A. and Ruiz-Medina, A. 2008. Implementation of Terbium-Sensitized Luminescence in Sequential-Injection Analysis for Automatic Analysis of Orbifloxacin. Anal. Bioanal. Chem., 392: 1397-1403.
49. Marín, P., Escudero, E., Fernández-Varón, E. and Cárceles, C. M. 2007. Pharmacokinetics and Milk Penetration of Orbifloxacin after Intravenous, Subcutaneous, and Intramuscular Administration to Lactating Goats. J. Dairy Sci., 90: 4219-4225.
50. Marín, P., Fernández-Varón, E., Escudero, E., Vancraeynest, D. and Cárceles, C. M. 2008. Pharmacokinetic-Pharmacodynamic Integration of Orbifloxacin in Rabbits after Intravenous, Subcutaneous and Intramuscular Administration. J. Vet. Pharmacol. Ther., 31: 77-82.
51. Martinez, M., Augsburger, L., Johnston, T. and Jones, W. W. 2002. Applying the Biopharmaceutics Classification System to Veterinary Pharmaceutical Products. Part I. Biopharmaceutics and Formulation Considerations. Adv. Drug Deliv. Rev., 54: 805-824.
52. Martinez, M., McDermott, P. and Walker, R. 2006. Pharmacology of the Fluoroquinolones: A Perspective for the Use in Domestic Animals. Vet. J., 172: 10-28.
53. Martínez-Martínez, L., Pascual, A. and Jacoby, G. A. 1998. Quinolone Resistance from a Transferable Plasmid. Lancet, 351(9105): 797-799.
54. Matsumoto, S., Takahashi, M., Yoshida, M., Komatsu, T., Kitadai, N., Horii, Y. and Katae, H. 1997. Absorption, Distribution and Excretion of Orbifloxacin in Dogs and Cats [in Japanese]. J. Jpn. Vet. Med. Assoc., 50: 470-474.
55. Matsumoto, S., Nakai, M., Yoshida, M. and Katae, H. A. 1999a. Study of Metabolites Isolated from Urine Samples of Pigs and Calves Administered Orbifloxacin. J. Vet. Pharmacol. Ther., 22: 286-289.
56. Matsumoto, S., Kitadai, N., Nakata, K. and Katae, H. 1999b. Combined In Vitro Effects of Orbifloxacin and Fosfomycin on S. dublin and S. typhimurium Isolated from Calves [in Japanese]. J. Jpn. Vet. Med. Assoc, 53: 1-6.
57. Matsumoto, S., Takahashi, M., Kitadai, N. and Katae, H. A. 1998a. Study of Metabolites Isolated from the Urine Samples of Cats and Dogs Administered Orbifloxacin. J. Vet. Med. Sci., 60(11): 1259-1261.
58. Matsumoto, S., Nakai, M., Yoshida, M. and Katae, H. 1998b. Absorption, Distribution and Excretion of Orbifloxacin in Swine and Calves [in Japanese]. J. Jpn. Vet. Med. Assoc., 51: 13-18.
59. McKay, L., Rose, C. D., Matousek, J. L., Schmeitzel, L. S., Gibson, N. M. and Gaskin, J. M. 2007. Antimicrobial Testing of Selected Fluoroquinolones against Pseudomonas aeruginosa Isolated from Canine Otitis. J. Am. Anim. Hosp. Assoc, 43: 307-312.
60. Morimura, T., Ohno, T., Matsukura, H. and Nobuhara, Y. 1995a. Photodegradation Kinetics of the New Antibacterial Fluoroquinolone Derivative, Orbifloxacin, in Aqueous Solution. Chem. Pharm. Bull., 43(6): 1000-1004.
61. Morimura, T., Ohno, T., Matsukura, H. and Nobuhara, Y. 1995b. Degradation Kinetics of the New Antibacterial Fluoroquinolone Derivative, Orbifloxacin, in Aqueous Solution. Chem. Pharm. Bull., 43(6): 1052-1054.
62. Morimura, T., Kohno, K., Nobuhara, Y. and Matsukura, H. 1997a. Photoreaction and Active Oxygen Generation by Photosensitization of a New Antibacterial Fluoroquinolone Derivative, Orbifloxacin, in the Presence of Chloride Ion. Chem. Pharm. Bull., 45(11): 1828-1832.
63. Morimura, T., Nobuhara, Y. and Matsukura, H. 1997b. Photodegradation Products of a New Antibacterial Fluoroquinolone Derivative, Orbifloxacin, in Aqueous Solution. Chem. Pharm. Bull., 45(2): 373-377.
64. Morioka, A., Asai, T., Ishihara, K., Kojima, A., Tamura, Y. and Takahashi, T. 2005. In vitro Activity of 24 Antimicrobial Agents against Staphylococcus and Streptococcus Isolated from Diseased Animals in Japan. J. Vet. Med. Sci., 67(2): 207-210.
65. Nakamura, S. 1995. Veterinary Use of New Quinolones in Japan. Drugs, 49(Suppl. 2): 152-158.
66. O'Neil, M. J. 2006. The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals, 14th ed., 1182Whitehouse Station, N.J.: Merck & Co.
67. Papich, M. G. and Riviere, J. E. 2001. "Fluoroquinolone Antimicrobial Drugs". In Veterinary Pharmacology and Therapeutics, 8th ed., Edited by: Adams, H. R. 898-917. Ames: Iowa State University Press.
68. Pirro, F., Edingloh, M. and Schmeer, N. 1999. Bactericidal and Inhibitory Activity of Enrofloxacin and Other Fluoroquinolones in Small Animal Pathogens. Compendium on Continuing Education for the Practicing Veterinarian, 21(Suppl. 12M): 19-25.
69. Regmi, N. L., Abd El-Aty, A. M., Kubota, R., Shah, S. S. and Shimoda, M. 2007. Lack of Inhibitory Effects of Several Fluoroquinolones on Cytochrome P-450 3A Activities at Clinical Dosage in Dogs. J. Vet. Pharmacol. Ther., 30: 37-42.
70. Riddle, C., Lemons, C. L., Papich, M. G. and Altier, C. 2000. Evaluation of Ciprofloxacin as a Representative of Veterinary Fluoroquinolones in Susceptibility Testing. J. Clin. Microbiol., 38: 1636-1637.
71. Rosser, E. J. 2004. Causes of Otitis Externa. Vet. Clin. North Am. Small Anim. Pract., 34: 459-468.
72. Rubin, J., Walker, R. D., Blickenstaff, K., Bodeis-Jones, S. and Zhao, S. 2008. Antimicrobial Resistance and Genetic Characterization of Fluoroquinolone Resistance of Pseudomonas aeruginosa Isolated from Canine Infections. Vet. Microbiol., 131: 164-172.
73. Saito, M., Kozutsumi, D., Kawasaki, M., Kanbashi, M., Nakamura, R., Sato, Y. and Endo, M. 2008. Multiresidue Method for Pesticides and Veterinary Drugs in Bovine Milk Using GC/MS and LC/MS/MS [in Japanese]. Shokuhin Eiseiqaku Zasshi, 49(3): 228-238.
74. Santoke, H., Song, W., Cooper, W. J., Greaves, J. and Miller, G. E. 2009. Free-Radical-Induced Oxidative and Reductive Degradation of Fluoroquinolone Pharmaceuticals: Kinetic Studies and Degradation Mechanism. J. Phys. Chem. A, 113: 7846-7851.
75. Sárközy, G. 2001. Quinolones: A Class of Antimicrobial Agents. Vet. Med, 46(9-10): 257-274.
76. Schneider, M. J. and Donoghue, D. J. 2002. Multiresidue Analysis of Fluoroquinolone Antibiotics in Chicken Tissue Using Liquid Chromatography-Fluorescence-Multiple Mass Spectrometry. J. Chromatogr. B, 780: 83-92.
77. Schneider, M. J. and Donoghue, D. J. 2003. Multiresidue Determination of Fluoroquinolone Antibiotics in Eggs Using Liquid Chromatography-Fluorescence-Mass Spectrometry. Anal. Chim. Acta, 483: 39-49.
78. Schneider, M. J., Vazquez-Moreno, L., Bermudez-Almada, M. C., Guardado, R. B. and Ortega-Nieblas, M. 2005. Multiresidue Determination of Fluoroquinolones in Shrimp by Liquid Chromatography-Fluorescence-Mass Spectrometry. J. AOAC Int., 88(4): 1160-1166.
79. Schneider, M. J., Reyes-Herrera, I. and Donoghue, D. J. 2007. Evaluation of Serum as a Potential Matrix for Multiresidue Determination of Fluoroquinolone Antibiotics in Chicken Using Liquid Chromatography-Fluorescence-Mass Spectrometry. J. AOAC Int., 90(6): 1716-1723.
80. Scott, D., Miller, W. H. and Miller, C. E. 2001. "Bacterial Skin Diseases". In Muller and Kirk's Small Animal Dermatology, 6th ed., Edited by: Muller, W. 274-335. Philadelphia: Saunders.
81. Scott, D. W., Peters, J. and Miller, W. H. Jr. 2006. Efficacy of Orbifloxacin Tablets for the Treatment of Superficial and Deep Pyoderma Due to Staphylococcus intermedius Infection in Dogs. Can. Vet. J, 47: 999-1002.
82. Shimoda, M., Abd El-Aty, A. M., Nakamura, M. and Kokue, E. 2003. Inhibitory Effects of Some Fluoroquinolones on Cytochrome P450 1A Activities of Canine Hepatic Microsomes. J. Vet. Pharmacol. Ther., 26(Suppl. 1): 111-112.
83. Shryock, T. R. 2001. NCCLS Quality Control Values for Veterinary-Use Fluoroquinolones [letter]. J. Clin. Microbiol, 39(4): 1680-1681.
84. Tabasi, S. H., Fahmy, R., Bensley, D., O'Brien, C. and Hoag, S. W. 2008a. Quality by Design, Part I: Application of NIR Spectroscopy to Monitor Tablet Manufacturing Process. J. Pharm. Sci., 97(9): 4040-4051.
85. Tabasi, S. H., Fahmy, R., Bensley, D., O'Brien, C. and Hoag, S. W. 2008b. Quality by Design, Part II: Application of NIR Spectroscopy to Monitor the Coating Process for a Pharmaceutical Sustained Release Product. J. Pharm. Sci., 97(9): 4052-4066.
86. Tabasi, S. H., Fahmy, R., Bensley, D., O'Brien, C. and Hoag, S. W. 2008c. Quality by Design, Part III: Study of Curing Process of Sustained Release Coated Products Using NIR Spectroscopy. J. Pharm. Sci., 97(9): 4067-4086.
87. U.S. Food and Drug Administration. April 22, 1997. Freedom of Information Summary: Orbax. NADA 141-081. 62(103), Rockville, MD: FDA. http://www.gpo.gov/fdsys/pkg/FR-1997-05-29/html/97-14107.htm (accessed 1/24/11).
88. U.S. Food and Drug Administration. Aug 22, 2010. Oral Dosage Form New Animal Drugs; Orbifloxacin Suspension. NADA 141-305. 75(91), Rockville, MD: FDA. http://www.gpo.gov/fdsys/pkg/FR-2010-05-12/html/2010-11245.htm (accessed 1/24/11)
89. U.S. Food and Drug Administration. NADA 141-081 Orbax™ - original approval [media release] 2011 Jan 30. http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm117014.htm (accessed 5/02/12). Latest update: April 26, 2012
90. 2011. U.S. Pharmacopeia, 34th ed, 3732-3734. Rockville, Md: United States Pharmacopeial Convention.
91. Walker, R. D. 2000. The Use of Fluoroquinolones for Companion Animal Therapy. Aust. Vet. J., 2: 8490
92. Yamada, R., Kozono, M., Ohmori, T., Morimatsu, F. and Kitayama, M. 2006. Simultaneous Determination of Residual Veterinary Drugs in Bovine, Porcine, and Chicken Muscle Using Liquid Chromatography Coupled with Electrospray Ionization Tandem Mass Spectrometry. Biosci. Biotechnol. Biochem., 70(1): 54-65.